- Home
- CCEL vs MAIA Comparison
CCEL vs MAIA Comparison
Compare CCEL & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- MAIA
- Stock Information
- Founded
- CCEL 1989
- MAIA 2018
- Country
- CCEL United States
- MAIA United States
- Employees
- CCEL N/A
- MAIA N/A
- Industry
- CCEL Managed Health Care
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- CCEL Health Care
- MAIA Health Care
- Exchange
- CCEL Nasdaq
- MAIA Nasdaq
- Market Cap
- CCEL 50.0M
- MAIA 52.7M
- IPO Year
- CCEL 1997
- MAIA 2022
- Fundamental
- Price
- CCEL $7.80
- MAIA $2.09
- Analyst Decision
- CCEL
- MAIA
- Analyst Count
- CCEL 0
- MAIA 0
- Target Price
- CCEL N/A
- MAIA N/A
- AVG Volume (30 Days)
- CCEL 13.9K
- MAIA 175.0K
- Earning Date
- CCEL 12-24-2024
- MAIA 11-12-2024
- Dividend Yield
- CCEL 3.14%
- MAIA N/A
- EPS Growth
- CCEL N/A
- MAIA N/A
- EPS
- CCEL N/A
- MAIA N/A
- Revenue
- CCEL $31,838,476.00
- MAIA N/A
- Revenue This Year
- CCEL $3.97
- MAIA N/A
- Revenue Next Year
- CCEL $0.91
- MAIA N/A
- P/E Ratio
- CCEL N/A
- MAIA N/A
- Revenue Growth
- CCEL 1.95
- MAIA N/A
- 52 Week Low
- CCEL $4.47
- MAIA $0.95
- 52 Week High
- CCEL $9.50
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- CCEL 45.13
- MAIA 45.13
- Support Level
- CCEL $7.60
- MAIA $1.93
- Resistance Level
- CCEL $9.10
- MAIA $2.63
- Average True Range (ATR)
- CCEL 0.27
- MAIA 0.20
- MACD
- CCEL -0.15
- MAIA 0.03
- Stochastic Oscillator
- CCEL 23.61
- MAIA 37.37
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.